HLUYY - Two More Clinical Failures Underline Lundbeck's High-Risk R&D Model
Drug development is an inherently risky and challenging endeavor, but not all drug development is the same. Some areas, including drugs for the central nervous system (or CNS), have notoriously below-average success rates, and H. Lundbeck’s (OTCPK:HLUYY) (LUN.CO) recent clinical failures provided yet another unwelcome reminder to investors that the clinical pipeline they’re counting on to restore the company to a growth trajectory carries a high level of risk.
The failures of foliglurax and LuAG06466 don’t impact my baseline fair value much at all, as I had assigned low probabilities